GlassScriptPhysician profile
John J Hobson
NPI 1124177431
$7,543.08
in general payments reported to CMS, 2019-2025
41 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,588 · 2020: $374 · 2021: $20.93 · 2022: $871 · 2023: $1,303 · 2024: $1,500 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,614 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,614.02 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $886.44 | 2019-2025 | |
| Novo Nordisk INC | $611.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $602.72 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Pfizer INC. | $564.07 | 2019-2025 | |
| Lilly USA, LLC | $521.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $470.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $350.35 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $324.04 | 2019-2025 | Evenity, Repatha, Otezla |
| Daiichi Sankyo INC. | $317.91 | 2019-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.09 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $275.71 | 2019-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $234.85 | 2019-2025 | Belsomra, Steglatro, Lagevrio |
| Novartis Pharmaceuticals Corporation | $215.35 | 2019-2023 | |
| Exact Sciences Corporation | $162.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $145.87 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.